Compare
Lantheus Holdings, Inc. vs QuidelOrtho Corp vs Neogen Corp vs Myriad Genetics Inc
| Latest fiscal year | Lantheus Holdings, Inc. LNTH | QuidelOrtho Corp QDEL | Neogen Corp NEOG | Myriad Genetics Inc MYGN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-28 | 2026-05-31 | 2025-12-31 |
| Revenue | $1.54B | $2.73B | $870.40M | $824.50M |
| Revenue growth (YoY) | +0.5% | -1.9% | -2.7% | -1.6% |
| Gross margin | 61.1% | n/a | 46.9% | 69.9% |
| Operating margin | 20.2% | -33.7% | -2.5% | -47.0% |
| Net margin | 15.2% | -41.5% | -0.9% | -44.4% |
| Net income | $233.56M | -$1.13B | -$7.90M | -$365.90M |
| EPS (Diluted) | $3.41 | -$16.69 | -$0.04 | -$3.95 |
| Operating cash flow | $390.14M | $105.20M | $83.20M | $1.80M |
| Free cash flow | n/a | -$83.00M | $31.90M | n/a |
| Cash & equivalents | $359.12M | $169.80M | $185.50M | $149.60M |
| Total assets | $2.23B | $5.77B | $3.35B | $706.60M |
| Total liabilities | $1.14B | $3.85B | $1.25B | $338.60M |
| Shareholders' equity | $1.09B | $1.92B | $2.09B | $368.00M |
| Return on year-end equity | 21.4% | -58.9% | -0.4% | -99.4% |
| Shares outstanding | 64.59M | 67.90M | 217.70M | 93.50M |
Revenue, most recent five fiscal years
| Fiscal year | Lantheus Holdings, Inc. | QuidelOrtho Corp | Neogen Corp | Myriad Genetics Inc |
|---|---|---|---|---|
| Latest | $1.54B Ended 2025-12-31 | $2.73B Ended 2025-12-28 | $870.40M Ended 2026-05-31 | $824.50M Ended 2025-12-31 |
| 1 year earlier | $1.53B Ended 2024-12-31 | $2.78B Ended 2024-12-29 | $894.70M Ended 2025-05-31 | $837.60M Ended 2024-12-31 |
| 2 years earlier | $1.30B Ended 2023-12-31 | $3.00B Ended 2023-12-31 | $924.20M Ended 2024-05-31 | $753.20M Ended 2023-12-31 |
| 3 years earlier | $935.06M Ended 2022-12-31 | $3.27B Ended 2023-01-01 | $822.45M Ended 2023-05-31 | $678.40M Ended 2022-12-31 |
| 4 years earlier | $425.21M Ended 2021-12-31 | $1.70B Ended 2022-01-02 | $527.16M Ended 2022-05-31 | $690.60M Ended 2021-12-31 |